Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
4
×
boston top stories
deals
4
×
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
startups
new york blog main
new york top stories
san diego blog main
san diego top stories
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
crispr therapeutics
detroit blog main
detroit top stories
gene therapy
indiana blog main
indiana top stories
investing
national
president trump
raleigh-durham blog main
raleigh-durham top stories
roche
san francisco
seattle blog main
seattle top stories
sherlock biosciences
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
acetylon pharmaceuticals
adverum biotechnologies
What
today
4
×
big
bio
biotech
crispr
drug
future
roundup
acquisitions
ahead
aiming
albert
ambien
ambys
american
annual
asco
attendees
attention
available
based
biggest
biosciences
bourla
camp’s
cancer
cas
cash
ceo
cheaper
chicago
city
clinical
combinations
community’s
company
control
days
deadly
deal
Language
unknown
unset
Current search:
today
×
" boston blog main "
×
deals
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?
@xconomy.com
6 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More